Form 4: Masimo EVP Tao Levy Reports Stock Transactions

Tao Levy, EVP of Business Development at Masimo Corp, reports acquisition of stock and derivative securities, including stock options and restricted stock units, while also disposing of shares to cover tax obligations.

Summary

• Tao Levy, an EVP at Masimo Corporation, filed a Form 4 detailing changes in beneficial ownership.
• On February 28, 2024, Levy acquired 1,004 shares of common stock at $0, resulting from the vesting of performance restricted stock units.
• Also on February 28, 2024, 401 shares were disposed of at $128.70 to cover tax obligations.
• Following these transactions, Levy directly owns 11,208 shares of common stock.
• On March 1, 2024, Levy was granted a non-qualified stock option to buy 7,390 shares at $126.49, vesting over five years.
• Additionally, on March 1, 2024, Levy was granted 30,000 restricted stock units (RSUs), with 50% vesting on March 1, 2025, and the remaining 50% vesting on March 1, 2026.
• The report also reflects the previously unreported withholding by the Issuer of 7,708 shares in 2021 and 4,926 shares in 2022 to cover tax obligations related to RSU vesting.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing showing standard executive compensation practices. The disposal of shares for tax obligations is a normal occurrence.

Positives

• The grant of stock options and restricted stock units to an executive suggests the company is incentivizing performance and aligning executive interests with shareholder value.

Negatives

• The disposal of shares to cover tax obligations, while common, slightly reduces the executive's direct stake in the company.

Risks

• Executive compensation packages, including stock options and RSUs, can be subject to scrutiny if not aligned with company performance or industry standards.

Future Outlook

The executive's holdings will change as stock options vest and are exercised, and as restricted stock units vest over the next two years.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The granting of stock options and RSUs is a common practice to incentivize executives in the healthcare technology industry.

Comparison to Industry Standards

• Stock option and RSU grants are common compensation tools in the medical device industry, used by companies like Medtronic, Stryker, and Boston Scientific to align executive incentives with shareholder value.
• Vesting schedules for stock options and RSUs typically range from three to five years, aligning with Masimo's five-year vesting period for the reported stock options.
• The size of the grants is relative to the executive's position and the company's overall compensation strategy, which is generally benchmarked against peer companies.

Stakeholder Impact

• Shareholders can monitor insider transactions to gain insights into management's confidence in the company.
• Employees may be impacted by executive compensation structures, as they can influence overall company performance and resource allocation.

Key Dates